Background Systemic Lupus Erythematosus (JSLE) is a severe autoimmune condition with lupus nephritis (LN) seen more frequently in juvenile disease where up to 80% have renal involvement . The renal biopsy is crucial for diagnosis and classification but has a limited role in monitoring. Current methods of monitoring renal disease activity over time rely on a variety of standard laboratory markers and the use of disease activity tools such as the British Isles Lupus Assessment Group index score (BILAG). Improving methods of monitoring and predicting disease activity may improve the long-term renal outcome.
Aims and methods This prospective longitudinal study aimed to identify whether standard and/or novel biomarkers are useful for monitoring and predicting LN disease activity. Using patients recruited to the UK JSLE study, urine and blood samples were collected during routine clinical reviews. The study had full ethical approval.
Results The JSLE cohort (n = 64), seen at 3 (interquartile range IQR: 2–5) clinical reviews over 364 (182–532) days were aged 14.1 (11.8–15.8) years and 80% female. Active renal episodes (23% total; renal BILAG A/B) had significantly increased concentration of; monocyte chemoattractant protein 1 (MCP1), neutrophil gelatinase associated lipocalin (NGAL), erythrocyte sedimentation rate, anti-double stranded DNA, urine albumin:creatinine ratio (UACR), creatinine, and reduced complement 3 (C3), C4 and lymphocytes. Cross sectional multivariate analysis demonstrated MCP1 and C3 as independent variables (p < 0.001) for active renal disease. Longitudinally, MCP1 was an excellent predictor of improved renal disease (area under the curve AUC: 0.81; p = 0.013; concentration 343pg/ml, specificity 71%, sensitivity 70%); NGAL was a good predictor of worsened renal disease activity (AUC 0.76; p = 0.04; concentration 30ng/ml, specificity 60%, sensitivity 61%). Standard markers could not predict disease activity changes.
Conclusion Novel biomarkers (MCP1, NGAL) are able to predict changes in JSLE related renal disease activity. Biomarker-led monitoring may facilitate earlier intervention to prevent renal damage. The development of point of care biomarker testing is now in progress.
Watson L, Leone V, Pilkington C, Tullus K, Rangaraj S, McDonagh JE, Gardner-Medwin J, Wilkinson N, Riley P, Tizard J et al. Arthritis Rheum 2012.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.